Aug 2026· Journal of Pulmonology and Intensive Care· Vol 4, pp. 79-87· 0 citations
TL;DR
Investigation of the relationship between recurrence and 18F-fluorodeoxyglucose positron emission tomography computed tomography parameters and prognostic factors found MTV may serve as a complementary prognostic biomarker to TNM staging in patients with early-stage NSCLC.
Abstract
Aims: Non-small-cell lung cancer (NSCLC) recurrence is high even after complete surgical resection. This study aimed to investigate the relationship between recurrence and 18F-fluorodeoxyglucose positron emission tomography computed tomography parameters and to determine prognostic factors.
Methods: Stage I–II NSCLC, confirmed through pathology after undergoing surgical resection were retrospective analyzed. Before surgery, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were derived by applying SUVmax-based thresholds of 2.5 and 42%. Data regarding demographics, clinicopathological features, and tumor characteristics were gathered. Kaplan–Meier method was used for disease-free survival (DFS) and overall survival rates. Prognostic factors causing recurrence were evaluated using univariate and multivariate Cox regression analysis.
Results: The average age of the 179 people included in the study was 61.24 years. Median follow up time was 50 months. Recurrence occurred in 38.5% of the patients. Prognostic factors for recurrence were larger tumor size, visceral pleural invasion, and PL2 involvement. When stratified by histology, MTV measured using SUVmax thresholds of 2.5 and 42% was significantly higher in patients with recurrence in the squamous cell carcinoma subgroup. In univariate analysis, high MTV42% was associated with shorter DFS. In multivariate analysis, MTV2.5 remained an independent predictor of DFS. SUVmax and TLG were not independently associated with DFS.
Conclusion: Disease-free survival was influenced by tumor size and the presence of pleural invasion. MTV may serve as a complementary prognostic biomarker to TNM staging in patients with early-stage NSCLC.
Objective: This study evaluates the prognostic significance of pretreatment [18F]FDG PET/CT metabolic parameters in esophageal cancer and identifies independent predictors of overall survival (OS). Methods: This retrospective single-center study included 152 treatment-naïve patients with histopathologically confirmed e...
OBJECTIVE
This study aimed to evaluate the prognostic value of serial PET/CT metabolic parameters and postoperative pathologic response separately, compare their predictive performance, and further assess their combined prognostic value in patients with non-small cell lung cancer (NSCLC) undergoing neoadjuvant immunoth...
You Cheng, Tian Qin, Fan Yang et al.· Clinical Nuclear Medicine· 0 citations
Introduction Circulating tumor DNA (ctDNA) is a valuable tool for assessing minimal residual disease (MRD) and predicting recurrence in resected non-small cell lung cancer (NSCLC) patients. Combining ctDNA-detection with radiological tumor volume may improve risk stratification. Methods Patients with stage I-III resect...
M. Verzè, R. Minari, P. Bordi et al.· The journal of liquid biopsy· 0 citations
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy (NST) is associated with improved outcomes in breast cancer. We evaluated the association between PET/CT-derived metabolic parameters and pCR and explored whether these associations differed according to molecular subtype. Methods:...
Z. Birsin, Mehmet Taner Bodur, S. Cebeci et al.· Diagnostics· 0 citations